Adaptimmune Therapeutics plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adrian G. Rawcliffe
- Full Time Employees
- 506
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Jubilee Avenue Abingdon United Kingdom OX14 4RX
- IPO Date
- May 6, 2015
- CIK
- 0001621227
- Website
- adaptimmune.com
- Similar Companies
- Business
- Adaptimmune Therapeutics plc (ADAPY), a clinical-stage biopharmaceutical company founded in 2008 and headquartered in Abingdon, Oxfordshire, United Kingdom, develops and commercializes engineered T-cell therapies targeting solid tumors, primarily serving cancer patients in the United States and United Kingdom; its core products include TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy approved by the U.S. FDA in August 2024 for adults with unresectable or metastatic synovial sarcoma expressing MAGE-A4; lete-cel, an investigational therapy for synovial sarcoma and myxoid/round cell liposarcoma; uza-cel (ADP-5701), in Phase 1 development for head and neck cancer through collaboration with Galapagos; and preclinical assets targeting PRAME (ADP-600) and CD70 (ADP-520), leveraging a proprietary T-cell receptor platform for personalized, single-dose treatments. The company operates as a fully integrated entity with capabilities in research, clinical development, manufacturing, and commercialization, focusing on challenging solid tumors like soft tissue sarcomas with limited treatment options. In July 2025, Adaptimmune entered a definitive agreement to sell TECELRA, lete-cel, afami-cel, and uza-cel to US WorldMeds for $55 million upfront plus up to $30 million in milestones, retaining rights to preclinical programs including PRAME, CD70, and allogeneic initiatives while restructuring to maximize value from remaining assets and ensure uninterrupted TECELRA access; in November 2025, it announced changes to its board and executive leadership to support this transition following FDA approval of its first biologics license application.
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Adaptimmune Announces Changes to Board and Executive Leadership Team
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Adaptimmune Announces Delisting from Nasdaq
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Reports Q3 2024 Financial and Business Updates
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Adaptimmune to Participate in Scientific and Medical Conferences this November and December